Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Regulatory News & FDA Approvals › Cue Health Nabs CE Mark for Molecular Point-of-Care COVID-19 Test

Cue Health Nabs CE Mark for Molecular Point-of-Care COVID-19 Test

Feb 23, 2021
|
staff reporter

NEW YORK ─ Cue Health said on Tuesday that it has received the CE mark for its molecular point-of-care COVID-19 test, clearing it for sale in the European Union and other regions that accept the designation.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

What's Popular?

In Regulatory News & FDA Approvals

  1. Mistakes Were Made in Regulation of SARS-CoV-2 Serology Tests, FDA Officials Acknowledge

    Premium

  2. Novacyt Obtains CE Mark for Extraction-Free COVID-19 PCR Test

  3. Kaya 17 Gets CE Mark for Point-of-Care Coronavirus Antigen Test

  4. FDA Issues New Guidance on SARS-CoV-2 Variants for Test Developers

  5. Cue Health Nabs CE Mark for Molecular Point-of-Care COVID-19 Test

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.